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Abstract
Background: Positron emission tomography (PET) with 18F-fluorodeoxyglucose
(FDG) is now a routine procedure for the management of cancer patients.
Intravenous administration of FDG is sometimes halted due to troubles. In such
cases, estimations of the FDG dosage injected prior to halting administration may be
helpful. We have established a method of estimating the activity of FDG to patients
on the basis of the dose equivalent rate on the surface of the right temporal region
of the head. The correlation of actual administered dosage with independent
variables, such as the dose equivalent rate on the right temporal region of the head,
age, sex, and body weight, was analyzed using multiple regression analysis to obtain
linear, quadratic, and cubic regression equations.
Results: When entering independent variables, the cubic regression equation could
be used to estimate an administered dosage with an accuracy of ±10 % for 62 % of
all patients and ±20 % for 90 % of all patients.
Conclusions: We conclude that this method is useful for estimating the
administered dosage from the dose equivalent rate on the temporal region of
the head.
Background
Exploiting the enhanced glucose uptake by tumor cells as compared with normal cells,
positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) is a routine
procedure for the management of cancer patients [1–3]. Intravenous administration of
FDG is sometimes halted due to extravasation of FDG, pain, or malfunction of injec-
tion devices. In such cases, estimations of the FDG dosage injected prior to halting ad-
ministration may be helpful in making a decision on how to proceed, whether to
perform venipuncture at a different site to inject additional FDG or to estimate the
eventual influence of underdosing on standardized uptake values (SUVs) and image
quality [4–6]. Thus, the activity remaining in the line and syringe may be estimated by
using a radionuclide calibrator. This, however, may increase unnecessary radiation ex-
posure to staffers because they have to handle the line and syringe and sometimes the
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injection device which may contain a large amount of radioactivity. To date, few studies
have attempted to establish methods for estimating the administered dosage against
such incomplete dosages immediately after administration was halted [7]. In this study,
the dose equivalent rate on the head of patients was assumed to give accurate estimates
of administered dosages. The aim of this study was to establish a method for estimating
the administered dosage based on variables including, dose equivalent rate on the right
temporal region of the head, age, sex, body weight (weight), height, elapsed time from
administration, and blood sugar using multiple regression analysis.
Methods
Patients and data collection
Seven hundred six patients underwent PET examination in our site during the period between
the 9th of March 2015 and the 23rd of May 2015. Of these, 520 patients were prospectively
enrolled in this study with Institutional Review Board approval. The requirement to obtain
informed consent was waived. The remaining 180 patients were not included in this study
because of refusal to be involved, unfavorable physical condition, or incomplete records.
Dosage calculation in our site:
AdministeredDosage MBq½  ¼ Int Weight kg½ 
10
 
 10 3 MBq=kg½  ð1Þ
where Int() is the function of “round down to the nearest decimal.” For example, for a
69-kg patient, 180 MBq is administered using an FDG automated injector (M130,
SUMITOMO Heavy Industries, Tokyo, Japan). After FDG administration, using an
FDG automated injector, the dose equivalent rate on the right temporal lobe (DER) was
measured with the patient sitting upright using an ionization chamber type survey
meter (ICS-323, HITACHI ALOKA). No patients voided their bladders between injec-
tion and dose-rate measurement. The right temporal lobe was chosen based on patient
comfort and the ability to conduct stable measurements. DER, administered dosage,
and elapsed time following FDG administration were recorded, as well as age, sex,
height, weight, and blood sugar. There are two reasons for having adopted the elapsed
time following FDG administration as a dependent variable, the first is to reflect the
physical decay and the second is to follow time-dependent uptake of the tracer in the
brain. All data were recorded by six nurses working in our PET institution.
Multiple regression analysis
This study was performed on a presupposition that DER should be in proportion to
AD. However, DER/AD (i.e., DER per unit dosage) is not completely a constant value.
DER/AD is influenced by patients’ characteristics, such as sex, elapsed time following
administration, patient age, height, weight, and blood sugar. Therefore, to achieve the
presuppositions, DER had to be converted to corrected DER (CDER), which was un-
affected by the influence of patients’ characteristics. The process of obtaining CDER is
demonstrated as follows. IBM SPSS statistics (International Business Machines Corpor-
ation) was employed for analysis and calculation of multiple regression analysis.
Figure 1 shows the scatter plot representing DER/administered dosage (DER/AD;
squares) on the vertical axis and weight on the horizontal axis. The DER/AD plot can
be used to determine a constant coefficient for each patient. In this plot, DER/AD
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decreases as weight increases. A correction coefficient can be calculated using the sin-
gle regression equation and the DER/AD and weight plots.
Correction Coefficient ¼ −0:013178 weightþ 2:181021 ð2Þ





−0:013178 weightþ 2:181021 DER ð3Þ
In Fig. 1, the plotted circles show no significant correlation between CDER/AD and
weight, demonstrating that the corrected DER is independent of weight. On the basis
of the above procedure of obtaining single regression analysis, the correction coefficient
for DER was calculated by stepwise multiple regression analysis with the dependent
variable DER/AD and independent variables of elapsed time, age, sex (dummy variables:
male = 1, female = 0), blood sugar, and either height or weight or body mass index





Here, it should be noted that weight, height, and BMI exhibit multicollinearity.
Therefore, the most appropriate variable, of the three, was determined using the Pear-
son test. The variable with the highest Pearson correlation coefficient was determined
to be the most important independent variable.
Next, an estimation of the administered dosage was calculated using CDER by linear,
quadratic, and cubic regression analyses.
Fig. 1 Scatter plot representing DER/AD. DER dose equivalent rate/administered dosage, AD administered
dosage, CDER corrected DER
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Linear : Estimated AdministeredDosage ¼ L 1ð Þ  CDER ð5Þ
Quadratic : Estimated Administered Dosage
¼ Q 1ð Þ  CDER2 þ Q 2ð Þ  CDER ð6Þ
Cubic : EstimatedAdministered Dosage
¼ C 1ð Þ  CDER3 þ C 2ð Þ  CDER2 þ C 3ð Þ  CDER ð7Þ
where L(1), Q(1), Q(2), C(1), C(2), and C(3) are regression coefficients, and the inter-
cept is zero.
Finally, the accuracy (residual rate) of the regression equations was calculated.
ResidualRate ¼ EstimatedAdministeredDose MBq½ 
AdministeredDose MBq½  −1 ð8Þ
Results
Test of normality
There were no significant differences in DER/AD among the nurses (data now shown).
Descriptive statistics and tests of normality, with the Shapiro-Wilk test results for each
of the dependent and independent variables, are shown in Tables 1 and 2. Table 2
shows the Shapiro-Wilk test p values for DER, DER/AD, height, and others variables.
Because the p values for DER and DER/AD were higher than 0.05, the null hypothesis
was not rejected, indicating that the DER and DER/AD data were normally distributed
and that the independent variables were appropriate for calculation of CDER with step-
wise multiple regression analysis.
Calculation of CDER with stepwise multiple regression analysis
The bivariate Pearson correlation coefficients for height, weight, and BMI (−0.452, −0.590,
and −0.414, respectively) are shown in Table 3. Because the Pearson correlation was highest
for weight, we adopted elapsed time, age, sex, blood sugar, and weight as independent
variables and performed stepwise regression analysis with these independent variables and
the dependent variable CDER/AD.
Table 4 shows the results of stepwise multiple regression analysis. The significance of
each independent variable was less than 0.01, indicating no influence, in all models, of
the independent variables on the dependent variable. All variance inflation factors
Table 1 Variables and statistics
Variables Mean ± SD Range Skewness Kurtosis
Administered dose [MBq] 152.7 ± 35.9 73.8–281.2 0.458 0.181
Elapsed time [s] 217.0 ± 95.1 36.0–620.0 0.001 −0.720
Dose equivalent rate [μSv/h] 210.6 ± 41.0 104.0–374.0 0.220 0.191
Height [cm] 160.7 ± 9.4 129.0–185.0 0.035 −0.376
Weight [kg] 58.12 ± 11.6 31.4–99.6 0.382 −0.185
Blood sugar [mg/dl] 112.6 ± 24.6 60.0–274.0 2.599 10.431
Age [years] 66.1 ± 12.2 18.0–91.0 −0.863 0.873
DER/AD [(μSv/h)/MBq] 1.41 ± 0.26 0.76–2.14 0.226 −0.103
Sex: male = 286; female = 234
DER/AD dose equivalent rate per administered dose
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(VIFs) were less than 1.30, indicating no multicollinearity. Therefore, model 4 was used
because it produced the highest adjusted R-square.
CorrectedCoefficient




−0:053893 Sexþ 0:000752 ElapsedTime‐0:011904Weight‐0:001987 BloodSugarþ 2:197180DER
ð10Þ
Figure 2 shows the normal P-P plot (a) and histogram of regression standardized re-
siduals (b). In Fig. 2a, plotted points deviating greatly from a straight line indicate that
the normality assumption was not met. The plotted points showed a good agreement
with the straight line. Figure 2b shows that the histograms were normally distributed
around zero. Moreover, the mean of residual rates was nearly zero. These results indi-
cate that the assumption of a normal distribution of residuals was satisfied.
Estimation of administered dosage with linear and nonlinear regression analysis
Figure 3 shows the scatter plot with CDER on the X-axis and administered dosage on
the Y-axis. Table 5 shows estimated parameters with linear, quadratic, and cubic regres-
sion equations for estimating the administered dosage. The adjusted R-square for linear,
quadratic, and cubic equations is 0.664 (moderate correlation), 0.744 (strong correl-
ation), and 0.747 (strong correlation), respectively.
Figure 4 shows the residual rates of histograms calculated by linear, quadratic, and
cubic estimations. These histograms showed that the residual rates were normally dis-
tributed around zero, and the mean of the residual rates was nearly zero. Using linear,
quadratic, and cubic regression equations, respectively, the administered dosage in
60.77 % (316/520), 61.92 % (322/520), and 61.92 % (322/520) of the patients could be
estimated with an accuracy of ±10 %. The above population percentages have been
Table 2 Shapiro-Wilk test of variables
Shapiro-Wilk test
W P value
Administered dose [MBq] 0.980 0.000
Elapsed Time [s] 0.878 0.000
Dose equivalent rate [μSv/h] 0.995 0.096
Height [cm] 0.993 0.020
Weight [kg] 0.987 0.000
Blood sugar [mg/dl] 0.780 0.000
Age [years] 0.955 0.000
DER/AD [(μSv/h)/MBq] 0.995 0.062
DER/AD dose equivalent rate per administered dose
Table 3 DER/AD and height, weight, and BMI
Height Weight BMI
DER/AD Pearson correlation −0.452 −0.590 −0.414
p value (2-tailed) 0.000a 0.000a 0.000a
DER/AD dose equivalent rate per administered dose
aCorrelation is significant at the 0.01 level (2-tailed)
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found to be 87.12 % (453/520), 90.00 % (468/520), and 90.20 % (469/520), respectively,
for an estimation accuracy of ±20 %.
Discussion
We have described a method to estimate the actual dosage of FDG administered using
corrected DER and four independent variables of sex, weight, blood sugar, and elapsed
time following administration in a cubic regression equation obtained by analyzing 520
patients. The ratio of DER over actual administered dosage becomes practically constant
when we correct DER using the independent variables, as indicated, by stepwise multiple
regression analysis. This method is useful for calculating the radioactivity of FDG admin-
istered to patients when administration must be halted for any reason. However, it does
not necessarily give a precise value of administered dosage but just an estimate. Care
should be taken when an administered dosage is estimated by our method and it may
affect the diagnostic interpretation or quantification of FDG accumulation. Of the four in-
dependent variables, the influence of blood sugar was less than weight and elapsed time
following administration in stepwise multiple regression analysis. This is interesting be-
cause usually blood sugar affects brain uptake of FDG [8, 9]. One proposed reason for the
decreased influence, of blood sugar on FDG uptake in the brain, might be that DER was
measured shortly after administration of FDG. Thus, the effect of blood sugar on brain
uptake was not large [10].
Because the proposed estimation method makes use of dose equivalent rates on the
surface of the right temporal lobe, other factors, that may affect brain uptake of FDG














1 (Constant) 0.346 2.181021 0.047049 46.356 0.000
Weight [kg] −0.013178 0.000793 −0.590 −16.614 0.000 1.000 1.000
2 (Constant) 0.414 2.022751 0.048944 41.327 0.000
Weight [kg] −0.013117 0.000751 −0.587 −17.465 0.000 1.000 1.000
Elapsed time
[s]
0.000713 0.000091 0.262 7.804 0.000 1.000 1.000
3 (Constant) 0.451 2.237429 0.059558 37.567 0.000
Weight [kg] −0.012969 0.000728 −0.580 −17.823 0.000 0.999 1.001
Elapsed Time
[s]
0.000743 0.000089 0.273 8.385 0.000 0.997 1.003
Blood sugar
[mg/dl]
−0.002040 0.000343 −0.194 −5.951 0.000 0.996 1.004
4 (Constant) 0.458 2.197180 0.060822 36.124 0.000
Weight [kg] −0.011904 0.000814 −0.533 −14.626 0.000 0.787 1.270
Elapsed time
[s]
0.000752 0.000088 0.277 8.542 0.000 0.995 1.005
Blood Sugar
[mg/dl]
−0.001987 0.000341 −0.189 −5.829 0.000 0.993 1.007
Sex −0.053893 0.018947 −0.104 −2.844 0.005 0.784 1.275
VIF variance inflation factor
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and, consequently, the accuracy of the method, should be considered. Diversion of
FDG to large tumors, leading to decreased brain uptake, has already been reported in
malignancies including lymphoma [11]. In this study, FDG uptake into tumors was not
included as a variable because routinely tumor uptake is unknown at the very time of
administration of FDG; thus, it cannot be incorporated in the estimation of the admin-
istered dosage.
One limitation of this study is that incomplete injection of FDG, in patients, was
not examined, which means that the in vivo predictive power of this estimation
method has not been verified. Of particular concern is the case of extravasation,
where measurement of the actual radioactivity of FDG injected into the circulation
is difficult to determine because FDG could be absorbed by subcutaneous tissue or
vascular tissue. DER is most likely associated with radioactivity injected into the
circulation. In time, the accuracy of our proposed estimation method can be
Fig. 2 Regression standardized residuals as normal P-P plot of a and histogram b
Fig. 3 Scatter plot with CDER and administered dosage. Solid line, linear; long dashed line, quadratic; short
dashed line, cubic
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verified using data accumulated from cases in which DER, the independent vari-
ables, and quantitative image data are all known. Another limitation is that this
study was conducted at only one facility. To establish such regression approaches,
including populations from multiple sites may be crucial to enhance generic applic-
ability and wide clinical adoption. Further, multi-center studies are needed to de-
termine the viability of our estimation method in PET facilities with various
clinical circumstances.
Conclusions
The actual administered dosage of FDG in patients was successfully estimated on the
basis of dose the equivalent rate using multiple regression analysis with four independ-
ent variables of sex, weight, blood sugar, and elapsed time following administration. We
propose using this method to determine the radioactivity of FDG administered to pa-
tients in cases of incomplete injection.




Lower bound Upper bound
L1 9.832E−001 5.747E−003 9.719E−001 9.945E−001
Q1 −1.328E−003 0.000E+000 −1.328E−003 −1.328E−003
Q2 1.216E+000 1.081E−004 1.216E+000 1.217E+000
C1 3.422E−006 1.491E−006 4.926E−007 6.352E−006
C2 −2.654E−003 5.878E−004 −3.809E−003 −1.499E−003
C3 1.336E+000 5.578E−002 1.227E+000 1.446E+000
Fig. 4 Residual rate histograms: linear a, quadratic b, and cubic c estimations
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